Southern African Treatment Resistance Network (SATuRN) RegaDB HIV drug resistance and clinical management database: supporting patient management, surveillance and research in southern Africa.

Database (Oxford)

Africa Centre for Health and Population Studies, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Mtubatuba, South Africa, Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK, Immunology department, University of Pretoria, Pretoria, South Africa, Infectious Diseases, Internal Medicine, University of the Free State School of Medicine, Bloemfontein, South Africa and Division of Medical Virology, Stellenbosch University, Stellenbosch, South Africa, National Health Laboratory Service Tygerberg, Cape Town, South Africa, Department of Virology, National Health Laboratory Service, University of KwaZulu-Natal, Durban, South Africa, The Brighton Doctoral College, Brighton and Sussex Medical School, UK, Academic Unit of primary Care and Population Science, Division of Social Statistics and Geography, University of Southampton, Southampton, UK, Jembi Health Systems, Cape Town, South Africa, School of Mathematics, Statistics and Computer Science, University of KwaZulu-Natal, Westville, South Africa and Research Department of Infection, University College of London (UCL), London, UK.

Published: August 2014

Substantial amounts of data have been generated from patient management and academic exercises designed to better understand the human immunodeficiency virus (HIV) epidemic and design interventions to control it. A number of specialized databases have been designed to manage huge data sets from HIV cohort, vaccine, host genomic and drug resistance studies. Besides databases from cohort studies, most of the online databases contain limited curated data and are thus sequence repositories. HIV drug resistance has been shown to have a great potential to derail the progress made thus far through antiretroviral therapy. Thus, a lot of resources have been invested in generating drug resistance data for patient management and surveillance purposes. Unfortunately, most of the data currently available relate to subtype B even though >60% of the epidemic is caused by HIV-1 subtype C. A consortium of clinicians, scientists, public health experts and policy markers working in southern Africa came together and formed a network, the Southern African Treatment and Resistance Network (SATuRN), with the aim of increasing curated HIV-1 subtype C and tuberculosis drug resistance data. This article describes the HIV-1 data curation process using the SATuRN Rega database. The data curation is a manual and time-consuming process done by clinical, laboratory and data curation specialists. Access to the highly curated data sets is through applications that are reviewed by the SATuRN executive committee. Examples of research outputs from the analysis of the curated data include trends in the level of transmitted drug resistance in South Africa, analysis of the levels of acquired resistance among patients failing therapy and factors associated with the absence of genotypic evidence of drug resistance among patients failing therapy. All these studies have been important for informing first- and second-line therapy. This database is a free password-protected open source database available on www.bioafrica.net. Database URL: http://www.bioafrica.net/regadb/

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630899PMC
http://dx.doi.org/10.1093/database/bat082DOI Listing

Publication Analysis

Top Keywords

drug resistance
28
patient management
12
curated data
12
data curation
12
data
11
resistance
10
southern african
8
african treatment
8
treatment resistance
8
resistance network
8

Similar Publications

Objective: The purpose of this study is to analyze the predictive value of neutrophil to lymphocyte ratio (NLR), lymphocyte count to monocyte count ratio (LMR), platelet to lymphocyte ratio (PLR), platelet count multiplied by neutrophil count to lymphocyte count ratio (SII), red blood cell distribution width (RDW), packed cell volume (PCV), and plateletcrit (PCT) levels in advanced non-small cell lung cancer (NSCLC) patients treated with PD-1/PD-L1 inhibitors.

Materials And Methods: From March 2019 to August 2023, we screened 104 of 153 patients with stage III unresectable local advanced NSCLC and IV NSCLC who received PD-1/PD-L1 inhibitor therapy at our hospital and met the inclusion and exclusion criteria for analysis. All patients were collected for clinical information, including baseline blood indicator (NLR, PLR, LMR, SII, CRP, RDW, PCV and PCT) levels before PD-1/PD-L1 inhibitor therapy and blood indicator levels and imaging evaluation results every two cycles after PD-1/PD-L1 inhibitor therapy.

View Article and Find Full Text PDF

Metabolic reprogramming induced by PSMA4 overexpression facilitates bortezomib resistance in multiple myeloma.

Ann Hematol

January 2025

Department of Hematology, Navy Medical Center of PLA, Naval Medical University, No. 338 West Huaihai Road, Changning District, Shanghai, 200052, China.

Multiple myeloma(MM) remains incurable with high relapse and chemoresistance rates. Differentially expressed genes(DEGs) between newly diagnosed myeloma and secondary plasma cell leukemia(sPCL) were subjected to a weighted gene co-expression network analysis(WGCNA). Drug resistant myeloma cell lines were established.

View Article and Find Full Text PDF

Background: The healthcare sector faces a growing threat from the rise of highly resistant microorganisms, particularly Methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Pseudomonas aeruginosa (MDR P. aeruginosa). Facing the challenge of antibiotic resistance, nanoparticles have surfaced as promising substitutes for antimicrobial therapy.

View Article and Find Full Text PDF

Carbapenem-resistant Klebsiella pneumoniae poses a severe risk to global public health, necessitating the immediate development of novel therapeutic strategies. The current study aimed to investigate the effectiveness of the green algae Arthrospira maxima (commercially known as Spirulina) both in vitro and in vivo against carbapenem-resistant K. pneumoniae.

View Article and Find Full Text PDF

Berberine‑calcium alginate-coated macrophage membrane-derived nanovesicles for the oral treatment of ulcerative colitis.

Int J Biol Macromol

January 2025

Pharmacy School, Jinzhou Medical University, Jinzhou, China; Liaoning Provincial Collaborative Innovation Center for Medical Testing and Drug Research, Jinzhou Medical University, Jinzhou, China; Key Laboratory of Medical Tissue Engineering of Liaoning Province, Jinzhou Medical University, Jinzhou, China. Electronic address:

In this study, we developed calcium alginate-coated nanovesicles derived from macrophage membranes loaded with berberine (Ber@MVs-CA) for the oral treatment of ulcerative colitis (UC). Ber@MVs-CA demonstrates resistance to gastric acid and controlled drug release in the colonic pH environment, while actively targeting sites of ulcerative colitis injury. pH-responsive release of Ber in Ber@MVs-CA was confirmed through in vitro release experiments.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!